{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:35:12Z","timestamp":1793316912415,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Psoriasis is an autoimmune disease that causes rapid turnover of skin cells. It is a chronic disease that affects a patient\u2019s quality of life significantly and frequently requires long-term treatment. The study on sequential therapy with tazarotene 0.1% and calcitriol 0.0003% has not been tried so far; hence, we designed this study to compare the safety and efficacy of sequential therapy with tazarotene 0.1% cream and calcitriol 0.0003% ointment versus monotherapy in mild-to-moderate stable plaque psoriasis (SPP). The objective of this study was to compare the safety and efficacy of topical sequential treatment with tazarotene followed by calcitriol, topical calcitriol followed by tazarotene, tazarotene monotherapy, calcitriol monotherapy, and compare the safety and efficacy of the sequential therapies with monotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was a single center, prospective parallel-group, active control, randomized study of 16 weeks duration (treatment for 8 weeks and follow-up for 16 weeks), randomized to either of the four groups, i.e., tazarotene 0.1% for 4 weeks followed by calcitriol 0.0003% for 4 weeks or calcitriol 0.0003% for 4 weeks followed by tazarotene 0.1% for 4 weeks or tazarotene 0.1% for 8 weeks or calcitriol 0.0003% for 8 weeks. Both tazarotene and calcitriol were applied once daily in all the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>There was no significant difference with regard to age and duration of illness among the four treatment groups. Statistically significant improvement was observed in erythema, scaling, and induration scores, and Physician`s global assessment scale at 8 weeks and 16 weeks as compared to baseline in tazarotene \u2013 calcitriol, calcitriol \u2013 tazarotene, and calcitriol versus tazarotene groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study concluded that topical treatment with tazarotene 0.1% and calcitriol 0.003% was efficacious in treating mild-to-moderate SPP as both sequential and monotherapy. However, topical treatment with tazarotene as monotherapy was the least efficacious.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_10_23","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T13:00:07Z","timestamp":1706706007000},"page":"44-48","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Head-to-Head Comparison of Tazarotene and Calcitriol with or without Sequential Therapy in Mild-to-Moderate Psoriasis: A Randomized Open-label Study"],"prefix":"10.4103","volume":"12","author":[{"given":"Jaspreet Kaur","family":"Sidhu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithpal Singh","family":"Matreja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani Kumar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. B R Ambedkar State Institute of Medical Sciences, Mohali, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shri Atal Bihari Vajpayee Government Medical College, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"R1-20240907","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13671-013-0066-6","article-title":"Genetic epidemiology of psoriasis","volume":"3","author":"Gupta","year":"2014","journal-title":"Curr Dermatol Rep"},{"key":"R2-20240907","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"R3-20240907","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R4-20240907","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2133.2006.07675.x","article-title":"Aclassification of psoriasis vulgaris according to phenotype","volume":"156","author":"Griffiths","year":"2007","journal-title":"Br J Dermatol"},{"key":"R5-20240907","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/2229-5178.193906","article-title":"Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring","volume":"7","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"R6-20240907","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.clindermatol.2007.08.003","article-title":"The clinical spectrum of psoriasis","volume":"25","author":"Naldi","year":"2007","journal-title":"Clin Dermatol"},{"key":"R7-20240907","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archderm.143.2.239","article-title":"National Psoriasis Foundation clinical consensus on disease severity","volume":"143","author":"Pariser","year":"2007","journal-title":"Arch Dermatol"},{"key":"R8-20240907","first-page":"34","article-title":"Evaluating new therapies for psoriasis","volume":"13","author":"Morrow","year":"2004","journal-title":"Manag Care"},{"key":"R9-20240907","first-page":"261","article-title":"Calcitriol ointment and clobetasol propionate cream: A new regimen for the treatment of plaque psoriasis","volume":"13","author":"Lahfa","year":"2003","journal-title":"Eur J Dermatol"},{"key":"R10-20240907","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/09546630305543","article-title":"Calcium homeostasis remains unaffected after 12 weeks'therapy with calcitriol 3 microg\/g ointment;no correlation with extent of psoriasis","volume":"14","author":"Barker","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"R11-20240907","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000247118","article-title":"Calcitriol (1 alpha, 25-dihydroxyvitamin D3) ointment in psoriasis, a safety tolerance and efficacy multicentre study","volume":"188","author":"Wishart","year":"1994","journal-title":"Dermatology"},{"key":"R12-20240907","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF01955893","article-title":"Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children","volume":"152","author":"Saggese","year":"1993","journal-title":"Eur J Pediatr"},{"key":"R13-20240907","first-page":"236","article-title":"Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis","volume":"85","author":"Tzung","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"R14-20240907","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/0378-6323.44302","article-title":"Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis","volume":"74","author":"Kaur","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R15-20240907","first-page":"12","article-title":"An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +\/- corticosteroid","volume":"66","author":"Tanghetti","year":"2000","journal-title":"Cutis"},{"issue":"Suppl 58","key":"R16-20240907","first-page":"17","article-title":"Long-term safety of topical calcitriol 3 microg g(-1) ointment","volume":"144","author":"Gerritsen","year":"2001","journal-title":"Br J Dermatol"},{"key":"R17-20240907","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.1996.d01-1009.x","article-title":"A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis","volume":"135","author":"Langner","year":"1996","journal-title":"Br J Dermatol"},{"key":"R18-20240907","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1365-2133.2003.05228.x","article-title":"Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas","volume":"148","author":"Ortonne","year":"2003","journal-title":"Br J Dermatol"},{"key":"R19-20240907","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1468-3083.2006.01913.x","article-title":"An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg\/g ointment versus calcipotriol 50 microg\/g ointment in subjects with mild to moderate chronic plaque-type psoriasis","volume":"21","author":"Zhu","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20240907","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/0019-5154.77550","article-title":"Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: An observer-blinded randomized controlled study","volume":"56","author":"Mehta","year":"2011","journal-title":"Indian J Dermatol"},{"key":"R21-20240907","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000091250","article-title":"Short contact therapy with tazarotene in psoriasis vulgaris","volume":"212","author":"Veraldi","year":"2006","journal-title":"Dermatology"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_10_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:16:54Z","timestamp":1787768214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_10_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_10_23","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2023-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}